Abstract:The candidate-gene approach in association studies of polygenic diseases has often yielded conflicting results. In this hospital-based case-control study with 696 white patients newly diagnosed with bladder cancer and 629 unaffected white controls, we applied a multigenic approach to examine the associations with bladder cancer risk of a comprehensive panel of 44 selected polymorphisms in two pathways, DNA repair and cell-cycle control, and to evaluate higher-order gene-gene interactions, using classification and regression tree (CART) analysis. Individually, only XPD Asp312Asn, RAG1 Lys820Arg, and a p53 intronic SNP exhibited statistically significant main effects. However, we found a significant gene-dosage effect for increasing numbers of potential high-risk alleles in DNA-repair and cell-cycle pathways separately and combined. For the nucleotide-excision repair pathway, compared with the referent group (fewer than four adverse alleles), individuals with four (odds ratio [OR] = 1.52, 95% CI 1.05-2.20), five to six (OR = 1.81, 95% CI 1.31-2.50), and seven or more adverse alleles (OR = 2.50, 95% CI 1.69-3.70) had increasingly elevated risks of bladder cancer (P for trend <.001). Each additional adverse allele was associated with a 1.21-fold increase in risk (95% CI 1.12-1.29). For the combined analysis of DNA-repair and cell-cycle SNPs, compared with the referent group (< 13 adverse alleles), the ORs for individuals with 13-15, 16-17, and >= 18 adverse alleles were 1.22 (95% CI 0.84-1.76), 1.57 (95% CI 1.05-2.35), and 1.77 (95% CI 1.19-2.63), respectively (P for trend = .002). Each additional high-risk allele was associated with a 1.07-fold significant increase in risk. In addition, we found that smoking had a significant multiplicative interaction with SNPs in the combined DNA-repair and cell-cycle-control pathways (P < .01). All genetic effects were evident only in "ever smokers" (persons who had smoked >= 100 cigarettes) and not in "never smokers." A cross-validation statistical method developed in this study confirmed the above observations. CART analysis revealed potential higher-order gene-gene and gene-smoking interactions and categorized a few higher-risk subgroups for bladder cancer. Moreover, subgroups identified with higher cancer risk also exhibited higher levels of induced genetic damage than did subgroups with lower risk. There was a significant trend of higher numbers of bleomycin- and benzo[a]pyrene diol-epoxide (BPDE)-induced chromatid breaks (by mutagen-sensitivity assay) and DNA damage ( by comet assay) for individuals in higher-risk subgroups among cases of bladder cancer in smokers. The P for the trend was .0348 for bleomycin- induced chromosome breaks, .0036 for BPDE-induced chromosome breaks, and .0397 for BPDE-induced DNA damage, indicating that these higher-order gene-gene and gene-smoking interactions included SNPs that modulated repair and resulted in diminished DNA-repair capacity. Thus, genotype/phenotype analyses support findings from CART analyses. This is the first comprehensive study to use a multigenic analysis for bladder cancer, and the data suggest that individuals with a higher number of genetic variations in DNA-repair and cell-cycle control genes are at an increased risk for bladder cancer, confirming the importance of taking a multigenic pathway-based approach to risk assessment.

Genetic Variants in Cell Cycle Control Pathway Confer Susceptibility to Bladder Cancer

Genetic Variants in Cell Cycle Control Pathway Confer Susceptibility to Lung Cancer

C8-04: Genetic Polymorphisms in Cell Cycle Control Pathways and Lung Cancer Risk

Bladder Cancer Predisposition: A Multigenic Approach to DNA-Repair and Cell-Cycle–Control Genes

Combined Effects of Cigarette Smoking, Gene Polymorphisms and Methylations of Tumor Suppressor Genes on Non Small Cell Lung Cancer: a Hospital-Based Case-Control Study in China

Association of selected polymorphisms of CCND1, p21, and caspase8 with colorectal cancer risk.

Susceptibility of XRCC3, XPD, and XPG genetic variants to cervical carcinoma.

Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions.

Genetic Variations in Base Excision Repair Pathway and Risk of Bladder Cancer: A Case-Control Study in the United States

Profiling of Genetic Variations in Inflammation Pathway Genes in Relation to Bladder Cancer Predisposition

High-order Interactions among Genetic Variants in DNA Base Excision Repair Pathway Genes and Smoking in Bladder Cancer Susceptibility.

Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer

Genetic Variants in the Wnt/β-Catenin Signaling Pathway As Indicators of Bladder Cancer Risk.

High-Order Interactions among Genetic Polymorphisms in Nucleotide Excision Repair Pathway Genes and Smoking in Modulating Bladder Cancer Risk

Evaluation Of Genetic Variants In Microrna-Related Genes And Risk Of Bladder Cancer

The Association of Rs710886 in Lncrna PCAT1 with Bladder Cancer Risk in a Chinese Population.

Study On Bladder Cancer Susceptibility And Genetic Polymorphisms Of Xpc, Xpg, And Cyp In Smokers And Non-Smokers

Potentially Functional Polymorphisms in Cell Cycle Genes and the Survival of Non-Small Cell Lung Cancer in a Chinese Population

Genetic Variations In Regulator Of G-Protein Signaling (Rgs) Confer Risk Of Bladder Cancer

Common Genetic Variants in Cell Cycle Pathway Are Associated with Survival in Stage III-IV Non-Small-cell Lung Cancer.

Genetic Variants in Telomere-Maintenance Genes and Bladder Cancer Risk.